AFP - Doubts linger about anti-cholesterol drug Vytorin
CHICAGO (AFP) — New clinical trials have increased doubts about the efficiency of Merck and Schering-Plough’s prized anti-cholesterol drug Vytorin and its ability to fight cardiovascular disease, according to medical data released here.
A group of distinguished cardiologists recommended taking high doses of statins to reduce bad cholesterol levels before prescribing only Vytorine or Zetia.
The clinical tests showed that Vytorin did not reverse arteriosclerosis, the hardening of the arteries, even if it did reduce cholesterol levels.
Vytorin produced no result, the study’s chief author John Kastelein, of the Academic Medical Center in Amsterdam, told the 57th annual meeting of the American College of Cardiology (ACC) here Sunday.
Related Results
Merck and Schering-Plough's statin combo hits pharmacies
Vytorin study raises questions about Cholesterol’s Import
Drug trials under pressure
WALL STREET CHOICE: SCHERING-PLOUGH SHOWS PROMISE
Girard Gibbs LLP Investigates Possible Securities Laws Violations Concerning …
Since it first went on sale in 2004, Vytorin has been prescribed to millions of Americans to aggressively reduce cholesterol levels. It costs four times as much as other generic anti-cholesterol drugs.
Vytorin combines Merck’s Zocor (simivastatine), …
Read the full article with a Free Trial at MyWire.
